In vitro experiments showed that increased hepatocellular steatosis and innate immune mediators after SHP knockdown and decreased innate immune responses following SHP overexpression indicate its role in suppressing hepatic steatosis and inflammation. The gene discussed is NR0B2; the disease is fatty liver disease.